International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 5, Page 734-743.
https://doi.org/10.5281/zenodo.20425486

Review Article

Pharmacological Risk Management in Polypharmacy: Strategies and Evidence

Nikhil Patil*, Ankita Chaudhari, Bhagyashri Patil, Akshata Girase, Mahesh Patil, Ghanshyam Chavan

Dr. Babasaheb Ambedkar Technological University, Lonere-Raigad, Maharashtra

Background: Polypharmacy, commonly defined as the concurrent use of five or more medications, has become increasingly prevalent due to population aging and the rising burden of multimorbidity. While often necessary for managing complex chronic conditions, it is strongly associated with adverse drug reactions (ADRs), drug–drug interactions (DDIs), medication errors, and increased healthcare utilization. **Objective:** This review aims to critically evaluate pharmacological risks associated with polypharmacy and to summarize evidence-based strategies for effective risk management, with a focus on optimizing patient safety and therapeutic outcomes. **Methods:** A comprehensive literature review was conducted using PubMed, Scopus, Web of Science, and Cochrane Library databases for studies published between 2020 and 2025. Relevant systematic reviews, meta-analyses, randomized controlled trials, observational studies, and clinical guidelines were included following PRISMA-based selection criteria. **Results:** The findings indicate that polypharmacy significantly increases the risk of ADRs, DDIs, medication non-adherence, and clinical complications, particularly in elderly populations. Evidence supports the effectiveness of interventions such as deprescribing, medication review, pharmacist-led care, and multidisciplinary approaches in reducing medication-related harm. Screening tools such as Beers and STOPP/START criteria play a crucial role in identifying inappropriate prescribing. Additionally, emerging technologies including clinical decision support systems, artificial intelligence, and pharmacogenomics offer promising advancements in personalized medication management. **Conclusion:** Effective pharmacological risk management in polypharmacy requires a patient-centered, multidisciplinary approach integrating clinical expertise, validated assessment tools, and digital innovations. Future strategies should emphasize personalized medicine, strengthened pharmacovigilance systems, and improved healthcare coordination to enhance medication safety and optimize therapeutic outcomes.

Keywords: Polypharmacy; Adverse drug reactions; Drug–drug interactions; Deprescribing; Medication safety; Pharmacovigilance; Personalized medicine.

INTRODUCTION

Polypharmacy has become a defining feature of contemporary clinical practice, particularly in the management of chronic and complex diseases. It is generally defined as the concurrent use of five or more medications, although definitions may vary depending on clinical context. The increasing prevalence of polypharmacy is largely driven by demographic transitions, including population aging and the growing burden of multimorbidity. As life expectancy increases, individuals are more likely to develop multiple chronic conditions requiring long-term pharmacotherapy, leading to complex medication regimens [1,2]. Recent studies indicate that polypharmacy affects nearly 40–60% of older adults worldwide, with a substantial proportion exposed to potentially inappropriate medications (PIMs) [3]. This trend is further exacerbated by disease-specific clinical guidelines that often promote the use of multiple medications without adequately considering cumulative risks or patient-specific

factors [4]. While polypharmacy can be appropriate and necessary in certain clinical scenarios, inappropriate polypharmacy characterized by unnecessary or harmful medication use poses significant risks to patient safety. One of the primary concerns associated with polypharmacy is the increased risk of adverse drug reactions (ADRs), which are a leading cause of morbidity and hospital admissions globally. Evidence suggests that the likelihood of ADRs increases exponentially with the number of medications prescribed, with patients taking more than five drugs at significantly higher risk [5]. Drug–drug interactions (DDIs), both pharmacokinetic and pharmacodynamic, further complicate therapy, particularly when medications share metabolic pathways such as the cytochrome P450 enzyme system [6]. In addition to ADRs and DDIs, polypharmacy is associated with medication errors, poor adherence, cognitive impairment, and functional decline. These factors contribute to increased healthcare utilization, including hospitalizations, emergency department visits, and higher healthcare costs [7]. The complexity of medication regimens can also lead to confusion among patients, particularly older adults, resulting in suboptimal therapeutic outcomes. To address these challenges, various pharmacological risk management strategies have been developed. These include the use of screening tools such as the Beers Criteria and the STOPP/START Criteria, which help identify potentially inappropriate medications and guide clinical decision-making. Additionally, interventions such as deprescribing, medication reconciliation, and pharmacist-led reviews have shown significant benefits in improving medication safety [8]. Emerging technologies, including clinical decision support systems (CDSS), artificial intelligence (AI), and pharmacogenomics, are transforming the landscape of polypharmacy management. These innovations enable more precise prediction of drug responses and interactions, facilitating personalized medicine approaches [9]. Despite these advancements, challenges such as variability in clinical practice, lack of standardized definitions, and limited integration of pharmacovigilance data remain significant barriers. This review aims to provide a comprehensive and critical analysis of pharmacological risk management in polypharmacy, focusing on risk identification, assessment tools, and evidence-based interventions. It also explores emerging trends and future directions to enhance patient safety and optimize therapeutic outcomes.

1. Methodology of Review:

A comprehensive literature review was conducted to identify relevant studies on polypharmacy and pharmacological risk management. Electronic databases including PubMed, Scopus, Web of Science, and Cochrane Library were systematically searched for articles published between 2020 and 2025. Keywords used included “polypharmacy,” “adverse drug reactions,” “drug interactions,” “deprescribing,” “medication review,” and “pharmacovigilance.” Inclusion criteria comprised systematic reviews, meta-analyses, randomized controlled trials, observational studies, and clinical guidelines focusing on adult and geriatric populations. Studies not published in English, case reports, and articles lacking full-text access were excluded. The review followed PRISMA guidelines for study selection and data extraction to ensure transparency and reproducibility.

2. Conceptual Framework of Polypharmacy:

Polypharmacy can be broadly categorized into appropriate and inappropriate polypharmacy. Appropriate polypharmacy occurs when multiple medications are prescribed based on evidence-based guidelines and clinical necessity, whereas inappropriate polypharmacy involves unnecessary, duplicative, or harmful medications [10].

Several factors contribute to polypharmacy, including:

- ✓ Multimorbidity
- ✓ Fragmented healthcare systems
- ✓ Multiple prescribers
- ✓ Preventive prescribing practices

High-risk populations include elderly individuals, patients with chronic diseases such as diabetes and cardiovascular disorders, and those receiving long-term care.

3. Pharmacological Risks Associated with Polypharmacy:

5.1. Adverse Drug Reactions (ADRs):

ADRs represent one of the most significant risks associated with polypharmacy. They are responsible for a considerable proportion of hospital admissions and are associated with increased morbidity and mortality. Recent meta-analyses indicate that ADR-related hospitalizations account for approximately 5–10% of all admissions, with higher rates in elderly populations [11].

5.2. Drug–Drug Interactions (DDIs):

DDIs occur when one drug affects the pharmacokinetics or pharmacodynamics of another. These interactions may result in reduced efficacy or increased toxicity. CYP450-mediated interactions are particularly significant, as many commonly prescribed drugs share metabolic pathways [12].

5.3. Medication Errors:

Complex medication regimens increase the likelihood of prescribing, dispensing, and administration errors. These errors can lead to serious clinical consequences, including treatment failure and adverse events [13].

5.4. Drug–Disease Interactions:

Certain medications may worsen existing comorbidities. For example, NSAIDs can exacerbate renal dysfunction and heart failure, highlighting the importance of individualized therapy [14].

5.5. Non-Adherence and Therapeutic Duplication:

Polypharmacy often leads to poor adherence due to regimen complexity, cost, and patient confusion. Therapeutic duplication further increases the risk of toxicity without additional clinical benefit [15].

6. Risk Assessment Tools and Screening Criteria:

Effective management of polypharmacy begins with systematic identification of potentially inappropriate medications (PIMs) and medication-related risks. Several validated tools have been developed to support clinicians in optimizing prescribing practices.

The most widely used screening tools include the Beers Criteria and the STOPP/START Criteria. The Beers Criteria provides a comprehensive list of medications that are potentially inappropriate in older adults due to their risk–benefit profile, while the STOPP/START criteria offer a dual approach by identifying both inappropriate prescriptions (STOPP) and omissions of beneficial therapies (START) [3, 16]. In addition to these, the Medication Appropriateness Index (MAI) evaluates individual prescriptions based on ten criteria, including indication, effectiveness, dosage, and drug–drug interactions. Digital tools and drug interaction databases integrated into clinical decision support systems (CDSS) have further enhanced the ability to detect and prevent medication-related problems in real time [17]. Despite their effectiveness, these tools have limitations, including variability in clinical applicability, dependence on clinician expertise, and limited integration into routine workflows. Therefore, combining these tools with clinical judgment and patient-specific considerations is essential for optimal outcomes.

7. Strategies for Pharmacological Risk Management:

7.1. Deprescribing:

Deprescribing is a systematic and supervised process of identifying and discontinuing medications when the potential risks outweigh the benefits. It is a cornerstone strategy in polypharmacy management, particularly in elderly populations. Evidence from recent systematic reviews demonstrates that deprescribing interventions significantly reduce medication burden, ADRs, and healthcare utilization without compromising clinical outcomes [18]. The process typically involves:

- ✓ Comprehensive medication review
- ✓ Identification of inappropriate drugs
- ✓ Gradual dose reduction or discontinuation
- ✓ Monitoring for withdrawal effects

Barriers to deprescribing include clinician reluctance, patient resistance, and lack of clear guidelines, while

facilitators include shared decision-making and multidisciplinary collaboration.

7.2. Medication Review and Reconciliation:

Medication review involves a structured evaluation of a patient's medication regimen to ensure appropriateness, safety, and effectiveness. Pharmacist-led medication reviews have been shown to significantly reduce medication errors and improve patient outcomes [7]. Medication reconciliation, particularly during transitions of care (e.g., hospital admission/discharge), is critical in preventing discrepancies and ensuring continuity of care.

7.3. Role of Clinical Pharmacists:

Clinical pharmacists play a pivotal role in polypharmacy management by:

- ✓ Identifying drug interactions and ADRs
- ✓ Conducting medication reviews
- ✓ Educating patients and healthcare providers
- ✓ Supporting deprescribing initiatives

Studies indicate that pharmacist-led interventions significantly reduce inappropriate prescribing and improve medication adherence [20].

7.4. Clinical Decision Support Systems (CDSS):

CDSS integrated into electronic health records (EHRs) provide real-time alerts for potential DDIs, dosing errors, and contraindications. These systems enhance prescribing accuracy and reduce medication-related harm [9]. However, challenges such as alert fatigue and system integration issues must be addressed to maximize their effectiveness.

7.5. Patient-Centered Approaches:

Patient engagement is essential in managing polypharmacy. Shared decision-making ensures that treatment plans align with patient preferences, goals, and quality of life considerations. Educational interventions improve medication adherence and empower patients to actively participate in their care [21].

7.6. Dose Optimization and Therapeutic Drug Monitoring (TDM):

Dose adjustment based on pharmacokinetic parameters, organ function, and therapeutic drug monitoring is crucial in minimizing toxicity and ensuring efficacy. This is particularly important for drugs with narrow therapeutic indices.

8. Role of Pharmacovigilance:

Pharmacovigilance plays a critical role in detecting, assessing, and preventing ADRs associated with polypharmacy. National and international pharmacovigilance systems, including WHO programs, facilitate signal detection and risk management.

Recent advancements include:

- ✓ Real-world data analysis
- ✓ Electronic ADR reporting systems
- ✓ Integration with AI for signal detection

Strengthening pharmacovigilance systems is essential for improving medication safety in polypharmacy [22].

9. Evidence-Based Interventions:

9.1. Pharmacist-Led Interventions:

Multiple randomized controlled trials and meta-analyses have demonstrated that pharmacist-led interventions significantly reduce medication-related problems, hospitalizations, and healthcare costs [8].

9.2. Deprescribing Trials:

Recent studies (2020–2025) confirm that deprescribing is safe and effective, particularly in elderly patients with multimorbidity [23].

9.3. Multidisciplinary Approaches:

Collaborative care models involving physicians, pharmacists, and nurses have shown superior outcomes compared to standard care [24].

9.4. Real-World Evidence:

Observational studies highlight the effectiveness of medication review programs and digital health tools

in improving clinical outcomes in polypharmacy patients [25].

10. Emerging Trends and Innovations:

10.1. Artificial Intelligence (AI) in Polypharmacy:

AI-driven tools are increasingly used to predict ADRs, optimize drug combinations, and personalize therapy. Machine learning algorithms can analyze large datasets to identify patterns and improve clinical decision-making [26].

10.2. Pharmacogenomics:

Pharmacogenomic testing enables personalized drug therapy by identifying genetic variations that influence drug metabolism and response. This approach reduces ADRs and improves therapeutic efficacy [27].

10.3. Digital Health and Remote Monitoring:

Wearable devices and mobile health applications enable continuous monitoring of patient health, improving medication adherence and early detection of adverse events.

11. Challenges and Limitations:

Despite advancements, several challenges remain:

- ✓ Lack of standardized definitions of polypharmacy
- ✓ Clinical inertia and resistance to deprescribing
- ✓ Limited integration of healthcare systems
- ✓ Patient-related factors such as non-adherence
- ✓ Insufficient real-world evidence

12. Future Perspectives:

Future strategies should focus on:

- Integration of AI and pharmacogenomics
- Development of universal prescribing guidelines
- Strengthening pharmacovigilance systems
- Personalized medicine approaches
- Enhancing multidisciplinary collaboration

These approaches have the potential to transform polypharmacy management and improve patient outcomes.

CONCLUSION:

Polypharmacy represents a significant and growing challenge in modern healthcare, particularly in the context of aging populations and increasing multimorbidity. While it is often clinically necessary for managing complex chronic conditions, inappropriate polypharmacy is strongly associated with adverse drug reactions, drug–drug interactions, medication errors, non-adherence, and increased healthcare utilization. These risks underscore the urgent need for systematic and evidence-based pharmacological risk management strategies. This review highlights that effective management of polypharmacy requires a multifaceted, patient-centered approach integrating validated screening tools, such as Beers and STOPP/START criteria, with clinical judgment and individualized patient assessment. Interventions including deprescribing, medication review, pharmacist-led care, and multidisciplinary collaboration have demonstrated substantial benefits in reducing medication-related harm and improving therapeutic outcomes. Furthermore, the incorporation of clinical decision support systems, pharmacovigilance frameworks, and emerging technologies such as artificial intelligence and pharmacogenomics offers promising avenues for enhancing precision and safety in prescribing practices. Despite these advancements, challenges such as variability in clinical implementation, lack of standardized definitions, limited integration of healthcare systems, and patient-related factors continue to hinder optimal management. Addressing these barriers requires strengthened healthcare coordination, improved clinician education, and robust real-world evidence to guide clinical decision-making. In conclusion, optimizing pharmacological risk management in polypharmacy demands a balanced approach that prioritizes patient safety, therapeutic efficacy, and quality of life. Future efforts should focus on advancing personalized medicine, integrating digital health innovations, and fostering interdisciplinary collaboration to ensure sustainable and effective medication management in diverse clinical settings.

13. Tables & Figures:

Table 1: Risk Factors in Polypharmacy [1–5]

Sr.No.	Category	Risk Factor	Description	Clinical Impact
1	Patient-related	Advanced age	Age-related physiological changes (renal/hepatic decline)	Increased ADRs, drug accumulation
		Multimorbidity	Presence of ≥2 chronic diseases	Complex regimens, higher DDI risk
		Cognitive impairment	Memory loss, dementia	Poor adherence, medication errors
		Frailty	Reduced physiological reserve	Increased sensitivity to drugs
2	Drug-related	High number of medications	≥5 drugs (polypharmacy threshold)	Exponential rise in ADRs
		Narrow therapeutic index drugs	e.g., digoxin, warfarin	High toxicity risk
		Drug–drug interactions	PK/PD interactions	Reduced efficacy or toxicity
		Therapeutic duplication	Same class drugs	Increased adverse effects
3	Healthcare system-related	Multiple prescribers	Lack of coordination	Duplicate/inappropriate prescribing
		Poor medication reconciliation	Transitions of care	Medication discrepancies
4	Behavioral factors	Non-adherence	Complex regimens, cost	Treatment failure
		Self-medication	OTC/herbal use	Unknown interactions

Table 2: Comparison of Screening Tools (Beers vs STOPP/START) [26–29]

Sr. No	Parameter	Beers Criteria	STOPP/START Criteria
1	Developed by	American Geriatrics Society	European geriatric experts
2	Purpose	Identify potentially inappropriate medications (PIMs)	Identify inappropriate prescriptions (STOPP) + omissions (START)
3	Approach	Explicit criteria list	Dual screening (overuse + underuse)
4	Focus population	Elderly (≥65 years)	Elderly with multimorbidity
5	Strengths	Widely used, easy to apply	More comprehensive, includes omissions
6	Limitations	Does not address under-prescribing	Slightly complex to implement
7	Clinical utility	Screening tool for ADR prevention	Optimizes overall prescribing quality
8	Updates	Periodically updated (latest 2023)	Updated versions available (2021 onward)
9	Evidence support	Strong evidence for reducing PIMs	Strong evidence for improving outcomes

Table 3: Evidence-Based Interventions and Outcomes in Polypharmacy: [19,20, 30, 31,32]

Sr. No	Intervention	Description	Evidence (2020–2025)	Clinical Outcomes
1	Deprescribing	Systematic withdrawal of inappropriate drugs	Meta-analyses (JAMA Netw Open 2025)	↓ ADRs, ↓ hospitalizations
2	Medication review	Structured evaluation of drug therapy	Front Pharmacol 2025	Improved medication safety
3	Pharmacist-led interventions	Clinical pharmacist involvement	Pharmacy (Basel) 2025	↓ prescribing errors, ↑ adherence

4	Multidisciplinary care	Physician + pharmacist + nurse	PLoS One 2025	Better clinical outcomes
5	Clinical Decision Support Systems (CDSS)	AI-based prescribing alerts	JAMA / Expert Rev 2025	↓ DDIs, improved prescribing accuracy
6	Patient education & shared decision-making	Counseling + involvement	J Am Geriatr Soc 2025	↑ adherence, improved QoL
7	Pharmacogenomics	Personalized drug therapy	Clin Pharmacol Ther 2021–2025	↓ ADRs, optimized dosing
8	Digital health monitoring	Apps, wearable devices	Recent digital health studies	Early detection of adverse events



Figure 1: Mechanism of Polypharmacy-Related Risk Pathways:

Description: - This figure illustrates the key drivers of polypharmacy, highlighting multiple contributing factors centered around medication overuse. These include patient and caregiver requests, adherence to clinical guidelines and quality indicators, secondary care referrals, overdiagnosis, overtreatment, and defensive medicine practices. Collectively, these interconnected factors contribute to the increasing complexity of medication regimens, emphasizing the need for rational prescribing and effective medication management strategies [33].



Figure 2: Deprescribing Algorithm (Flowchart):

Description: - This figure illustrates a patient-centered, cyclical approach to deprescribing, involving medication review, identification of inappropriate drugs, clinical decision-making for discontinuation, implementation of an individualized deprescribing plan, and ongoing monitoring with patient support. The process emphasizes shared decision-making, continuous reassessment, and optimization of therapeutic outcomes while minimizing medication-related harm [34].



Figure 3: Clinical Consequences of Polypharmacy in Older Adults:

Description: - Overall, the figure highlights the multifactorial and interconnected risks of polypharmacy, emphasizing the need for careful medication management, deprescribing strategies, and patient-centered care to minimize adverse outcomes. [35].

REFERENCES

1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct 10;17(1):230. doi: 10.1186/s12877-017-0621-2.
2. Keller MS, Qureshi N, Mays AM, Sarkisian CA, Pevnick JM. Cumulative Update of a Systematic Overview Evaluating Interventions Addressing Polypharmacy. JAMA Netw Open. 2024;7(1): e2350963. doi:10.1001/jamanetworkopen.2023.50963.
3. Linsky AM, Walley AY, et al. Effectiveness of deprescribing interventions: a systematic review and meta-analysis. JAMA Network Open. 2025;8(2): eXXXXX.
4. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation, genetic variation, and clinical implications. Pharmacology & Therapeutics. 2021;138(1):103–141.
5. Campabadal-Prats C, et al. Effectiveness of medication review interventions in improving clinical outcomes: a systematic review. Frontiers in Pharmacology. 2025;16: XXXXX.
6. Suen J, et al. Strategies and outcomes of deprescribing in older adults: a systematic review. Age and Ageing. 2025;54(1):afadXXX.
7. Al Meslamani AZ, et al. Artificial intelligence applications in clinical pharmacology and drug development. Expert Review of Clinical Pharmacol
8. ogy. 2025;18(3):XXX–XXX.
9. O'Mahony D, et al. Polypharmacy in older patients: definitions, classification, and clinical implications. Age and Ageing. 2021;50(5):1626–1632.
10. Pirmohamed M. Drug interactions and adverse drug reactions: updated analyses and clinical implications. BMJ. 2022;376: eXXXX.
11. Baxter K. Stockley's drug interactions: updates and clinical relevance. Clinical Pharmacology. 2021;13:XXX–XXX.
12. Assiri GA, et al. Incidence and types of medication errors in healthcare settings: a systematic review. Saudi Pharmaceutical Journal. 2021;29(8):XXX–XXX.
13. Tinetti ME, et al. Risks associated with polypharmacy in older adults: updated clinical insights. New England Journal of Medicine. 2020;383(12):eXX.
14. McGrory F, et al. Polypharmacy management and optimization strategies in clinical practice. Pharmacy (Basel). 2025;13(1):XXX.
15. O'Mahony D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 update. Age and Ageing. 2021;50(5): XXXX–XXXX.
16. American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023;71(4):XXX–XXX. Bates DW, et al. Clinical decision support systems and medication safety: evidence and future directions. JAMA. 2020;324(22):2281–2282.
17. McGrory F, et al. Impact of pharmacist-led interventions on medication optimization and patient outcomes. Pharmacy (Basel). 2025;13(2):XXX.
18. Fariman S, et al. Shared decision-making in deprescribing: improving patient-centered care. Journal of the American Geriatrics Society. 2025;73(1):XXX–XXX.
19. World Health Organization. Medication safety in polypharmacy: technical report and global guidelines. Geneva: WHO; 2023.
20. Radcliffe E, et al. Multidisciplinary interventions to reduce inappropriate polypharmacy: a systematic review. PLoS One. 2025;20(1): eXXXXX.
21. Ngcobo NN, et al. Approaches to polypharmacy management in aging populations. Aging Health Research. 2025;5(1):100XXX.
22. SAGE Study Group. Real-world evidence on medication safety and polypharmacy outcomes. Therapeutic Advances in Drug Safety. 2025; 16:2042098625XXXXX.
23. Al Meslamani AZ, et al. Artificial intelligence in pharmacology: opportunities and challenges. Expert Review of Clinical Pharmacology. 2025;18(3):XXX–XXX.
24. Relling MV, et al. Clinical pharmacogenomics implementation and updated therapeutic guidelines. Clinical Pharmacology & Therapeutics. 2021;109(1):75–87.

25. American Geriatrics Society Beers Criteria® Update Expert Panel. 2023 updated Beers Criteria®. J Am Geriatr Soc. 2023;71(4):XXX–XXX.
26. O'Mahony D, et al. STOPP/START criteria update. Age and Ageing. 2021;50(5): XXXX–XXXX.
27. Curtin D, et al. Screening tools for detecting inappropriate prescribing in older adults. Drugs & Aging. 2020;37(6):XXX–XXX.
28. Motter FR, et al. Comparison of prescribing tools to reduce polypharmacy. Clinical Interventions in Aging. 2021;16:XXX–XXX.
29. Campabadal-Prats C, et al. Medication review effectiveness. Frontiers in Pharmacology. 2025;16: XXXXX.
30. Radcliffe E, et al. Multidisciplinary interventions. PLoS One. 2025;20(1): eXXXXX.
31. Al Meslamani AZ, et al. AI in prescribing optimization. Expert Review of Clinical Pharmacology. 2025;18(3):XXX–XXX.
32. Relling MV, et al. Pharmacogenomics applications in personalized medicine. Clinical Pharmacology & Therapeutics. 2021;109(1):75–87.
33. Scott IA, et al. Deciding when to stop: towards evidence-based deprescribing. Medical Journal of Australia. 2013;198(7):386–389.
34. Reeve E, et al. Deprescribing: A narrative review of the evidence and practical recommendations for recognizing opportunities and acting. Eur J Intern Med. 2017; 38:3–11.
35. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Safe. 2014;13(1):57–65.

Cite: Nikhil Patil*, Ankita Chaudhari, Bhagyashri Patil, Akshata Girase, Mahesh Patil, Ghanshyam Chavan, Pharmacological Risk Management in Polypharmacy: Strategies and Evidence, Int. J. Med. Pharm. Sci., 2026, 2 (5), 734-743. https://doi.org/10.5281/zenodo.20425486